Tags Posts tagged with "ZYNE"

ZYNE

1 4439

Cannabis stocks have come down from their recent highs and this has raised some concerns after we ended 2016 on a high note.

2016 was a great year for the cannabis industry and we expect 2017 to build off this success. From Canada to Australia, the United States to Germany, the global cannabis industry continued to expand and the stage is set for growth for years to come.

The recent weakness has led to an influx of questions pertaining to the top cannabis investment opportunities and we want to highlight 7 cannabis stocks that investors should watch during 2017.

Seven Cannabis Stocks to Watch

1. GW Pharmaceuticals (GWPH): We continue to view GWPH as the top long-term biotech investment levered to the cannabis industry and we expect to see a VERY STRONG second half of the year. We are favorable on the long-term outlook due to its deep pipeline of products in advanced stages of clinical trials, its strong balance sheet, and its favorable Wall Street coverage.

2. Zynerba Pharma (ZYNE): We consider the company to be one of the most undervalued biotech investment opportunities. Zynerba is focused on developing treatments from synthetic cannabis and the average Wall Street price target offers almost 100% upside to current levels.

3. Canopy Growth (WEED.TO) (TWMJF) continues to be the leader in the Canadian medical cannabis industry and view the company as one the best opportunities within the cannabis industry. The shares have been trending lower and we view this weakness as a great opportunity to buy into a high-quality cannabis producer with a global footprint.

4. Emblem Corp. (EMC.V) (EMMBF) has been trending so far this year and the shares are down 30% during this time. Despite the recent weakness, we are bullish on the company’s opportunity due to its attractive business model, its proven management team, its sound financial structure, its strong balance sheet, and its leverage to growth trends in the cannabis sector

5. After securing a potentially highly lucrative licensing contract, InMed Pharmaceuticals, (IN.CN) (IMLFF) looks even better positioned to benefit for positive tailwinds facing the global cannabis industry. InMed is a pre-clinical biopharmaceutical company that is focused on the research and development of novel and cannabinoid-based therapies in Canada. The company has a strong pipeline of products in various stages of FDA testing and is developing various drugs for diseases, such as ocular, pain and inflammation.

6. VPR Brands, LP, (VPRB) is a stock to watch as it is levered to several growth trends within the global cannabis industry. The shares have pulled back and we see upside to current levels. In 2016, VPR acquired Vapor Corp’s wholesale operations and assets for a significant discount and recent announcements show that VPR has executed on and monetized this acquisition. We view this as a very attractive growth story that is undervalued by the street.

7. Vinergy (VIN.CN) (VNNYF) has been one of the most interesting and exciting stories to watch over the last six months and we see significant upside to current levels. The shares have fallen more than 33% in the last month and we find them to be attractive due to the number of catalysts for growth over the next year.

Disclaimer:
Pursuant to an agreement between MAPH and InMedPharmaceuticals., we were hired for a period beginning February 24 2017 and ending April 24, 2017 to publicly disseminate information about (IMLFF) including on the Website and other media including Facebook and Twitter. We are being paid $40,000 (CASH) for and were paid “250,000” shares of restricted common shares of InMed Pharmaceuticals.Pursuant to an agreement between MAPH and VPRBrands, we were hired for a period of 90 days to publicly disseminate information about (VPRB) including on the Website and other media including Facebook and Twitter. We are being paid $45,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VPRB) which we purchased in the open market. Pursuant to an agreement between MAPH and Vinergy Resources, we were hired for a period of 2 months to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $120,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market. We may buy or sell additional shares of (IMLFF, VPRB, VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 3044

Countries across the globe continue to legalize cannabis and it is only a matter of time until the U.S. gets on the bandwagon.

The biotech sector will be one of the greatest beneficiaries of legal cannabis and companies focused on this opportunity have outperformed the market over the last quarter.

A Stock to Watch

Today, Vinergy Resources (VIN: CSE) (VNNYF: OTCQB) reported a breakthrough while conducting R&D on its oral cannabinoid (CBD) delivery strips and controlled time release capsule technology.

We highlighted VIN.CN as a stock to watch after its acquisition of MJ Biopharma in mid-December and the market responded very favorably to this all-stock purchase. MJ Biopharma is a private cannabis technology company focused on manufacturing breath strips, time release capsules, extract oils, food products such as infused juices, teas, coffee and extract drinks, as well as the development of pharmaceutical grade delivery systems.

MJ Biopharma is also focused on licensing and partnering on the development of technologies and products for the medical and recreational cannabis market in Canada and abroad. The company said that the novel approach that is under development will become the basis for new products where water or saliva is the catalyst used to activate the carrier for delivery and absorption of CBD in the body.

Opportunity to Create a New Product Category

This unique approach forms the basis for a fundamentally new technology and possible new product category. The technology is called BURST due to the speed at which it can enhance the body’s absorption of various ingredients. The BURST system is built on natural botanical polymers delivering specialty processed high purity cannabinoids.

MJBiopharma CEO Kent Deuters said, “This is a great breakthrough for us and the product line we have planned. The technology can also be utilized in our time release capsules which of course will have a slower absorption rate. We think time release capsules are extremely important as they help bridge the gap in terms of familiarity with many patients who want to switch from synthetic drugs to a natural drug as a way to reduce side effects, reduce drug costs and just feel better all around.”

Two Top Picks

Two other biotech cannabis stocks we are watching are Zynerba Pharmaceuticals (ZYNE) and GW Pharmaceuticals (GWPH).

GWPH has rallied off its recent lows and we remain bullish on the company due to its deep pipeline of pharmaceutical products that are in advanced stages of FDA testing. The company has several catalysts in the back half of 2017 and we see significant upside to current levels.

ZYNE continues to remain one of our top picks in the cannabis sector as we see significant upside to current levels. The average Wall Street price target on ZYNE is north of $30 and we view the company as an acquisition candidate for any biotech company interested in the cannabis industry.

We continue to view GWPH as one of the top investment opportunities within the cannabis sector as it is the only Nasdaq traded company focused on developing treatments from the actual cannabis plant.

Unlike Zynerba Pharmaceuticals (ZYNE) which develop its treatments from synthetic cannabis, GWPH uses the actual cannabis plant and the benefits of this are reflected in its continued success in FDA trials.

0 1561

From the National Cancer Institute (NCI) to the National Institute on Drug Abuse (NIDA), U.S. government agencies continue to change its stance pertaining to medical cannabis.

Last year, the NCI updated its website to include various studies that reveal how cannabis may inhibit tumor growth by killing cells. The NIDA revised their April 2015 publication to say that marijuana can kill certain cancer cells and reduce the size of others.

Countries across the globe continue to legalize cannabis and it is only a matter of time until the U.S. gets on the bandwagon. Although the market continues to keep its eyes on the U.S. cannabis industry, its neighbors to the north continue to be the global cannabis leader.

Biotech Bets

The biotech sector will be one of the greatest beneficiaries of legal cannabis and companies focused on this opportunity have outperformed the market over the last quarter.

We highlighted Vinergy Resources (VIN.CN) as a stock to watch after its acquisition of MJ Biopharma in mid-December and the market responded very favorably to this all-stock purchase.  At the time of this announcement, Vinergy also announced a non-brokered private placement offering of up to 10,000,000 units at $0.20 per unit.

MJ Biopharma is a private cannabis technology company based out of British Columbia that is currently focused on manufacturing breath strips, time release capsules, extract oils, food products such as infused juices, teas, coffee and extract drinks, as well as the development of pharmaceutical grade delivery systems. The company is also focused on licensing and partnering on the development of technologies and products for the medical and recreational cannabis market in Canada and abroad.

Vinergy’s market sentiment has improved significantly following the acquisition and investors were able to acquire stock at a more than 50% discount to the current price through the private placement. The offering generated incredible interest and is very oversubscribed. Investors should keep an eye on Vinergy as we expect to see the company build off of this momentum.

An Agreement Based on Success

One of the reasons why we were favorable on the aquisiton of MJ BioPharma was due to the milestone-based compensation strucutre. Vinergy issued 5 million shares to MJ BioPharma shareholders and can issue up 3.75 million more shares based on the completion of certain milestones.

  • The company will issue an additional 2.75 million shares upon the commercialization of MJ BioPharma’s strip technology.
  • One million shares will be issued when each of two alternative selected extractions/products are ready for commercialization.

Banking on Biotech

Although we continue to expect the biotech sector to benefit the legal cannabis movement, we are watching how these companies are impacted by a new White House administration.

The biotech sub-sector of the cannabis industry is comprised of some of the most mature cannabis businesses. We continue to view these companies as some of the most attractive cannabis investments and want to discuss our view of these companies at their current levels.

GW Pharmaceuticals (GWPH) has rallied off its recent lows and we remain bullish on the company due to its deep pipeline of pharmaceutical products that are in advanced stages of FDA testing. The company has a number of catalysts in the back half of 2017 and we see significant upside to current levels.

Zynerba Pharmaceuticals (ZYNE) continues to remain one of our top picks in the cannabis sector as we see significant upside to current levels. The average Wall Street price target on ZYNE is north of $30 and we view the company as an acquisition candidate for any biotech company interested in the cannabis industry.

Insys Therapeutics (INSY) has also rallied off its recent lows and the shares fell more than 60% during 2016. We believe that all of the legal concerns are priced into INSY and see significant upside to current levels. Like Zynerba, we view Insys as an acquisition candidate and view the company as a long-term investment opportunity.

 

Join Technical420 and Capitalize on the Rapidly Growing Cannabis Industry…

 

Important Investor Disclosures 

Disclosure.  Compensated Affiliate.  This report was authored by and is property of StoneBridge Partners LLC.  All information and data relied upon in drafting this report is publicly available.  The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report.  Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice.  Any projections or other information generated by StoneBridge Partners LLC regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results.  None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment.  This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation.  The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals.  It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction.  Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks.  The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission.  Please contact a Financial Advisor for professional advice regarding any and all securities investments.  This report is intended for informational purposes only.  StoneBridge Partners LLC’s officers, directors, employees, affiliates, or subsidiaries may have positions in securities covered by StoneBridge Partners LLC.  StoneBridge Partners LLC receives compensation from the company and/or has a position in the securities mentioned in this report

 

Authored by: Micheal Berger

0 4892

Despite favorable state-wide election results, concerns among cannabis investors have increased and cannabis stocks continue to move lower following an overextended industry wide rally as well as highly questionable cabinet nominations by president elect Donald Trump.

Although the recent downward trend is concerning, this weakness has created an opportunity for investors to purchase high quality cannabis investments at a considerable discount.

Today, we want to take the time to highlight three recent trends and price movements that investors should be aware of.

Kush Bottles Falls Almost 20% from Last Week’s High

Kush Bottles (KSHB) has fallen more than 18% from its highs on Tuesday and the shares are now trading below the $3 price target issued by Cowen and Company in mid-September. The analyst assigned the shares a Buy rating and a $3 price target because of its unique exposure to the high growth, emerging cannabis industry.

This correction has created a great opportunity for investors as consider Kush Bottles to be one of the best cannabis investment opportunities. We are favorable on Kush Bottles due to the product it provides, its geographic diversity, its growth potential following positive state-wide election results and its continued execution.

The company offers several child resistant and non-child resistant exit bag solutions, all of which are fully customizable, allowing Kush Bottles’ customers the opportunity to creatively market and brand themselves. We find this aspect of its offering to be extremely important as companies compete to become a recognized brand amongst consumers.

Zynerba Fall More than 12% from Friday’s Highs

Zynerba Pharmaceuticals (ZYNE) fell approximately 3% yesterday and we are monitoring ZYNE closely as the shares are down almost 12% from its highs on Friday. This move lower has caused momentum to plunge and we remain favorable on ZYNE at current levels.

Investors should take note of Zynerba’s recent correction since it has followed a more than 15% rally so far this month. We consider Zynerba to be one of the top biotech cannabis investment opportunities due to:

1) its product pipeline, which will create catalysts for the shares over the next few years, 2) its attractive size (from a market cap standpoint) as it is a takeout candidate for a larger pharmaceutical company looking to enter the cannabis sector, and 3) its attractive valuation as the shares come down from recent highs.

Canadian Licensed Medical Cannabis Producers Bounce Back

Although yesterday’s trading activity within the cannabis sector was mixed, certain sub-sectors performed better than other and we are monitoring this activity closely. Canadian licensed medical cannabis producers saw strength yesterday and each member of the Big Five (Canopy Growth, OrganiGram, Aphria, Aurora, and Mettrum) ended the day in positive territory.

Yesterday, Emblem Corp (EMC.V) lived up to the hype during its initial public offering as trading activity exceeded our already high expectations. Emblem is a licensed medical cannabis producer in Canada uniquely positioned within the rapidly growing medical and recreational cannabis industry.

We are favorable on Emblem for the following reasons: 1) The company operates three distinct divisions which can create value for each other, 2) Its initial public offering saw remarkably high interest from the marketplace, 3) Its Emblem Cannabis division started selling medical cannabis in August and we expect to see continued growth on a month-over-month basis, and 4) It is led by a management team that has a proven track record of building successful multi-billion dollar companies.

Important Investor Disclosures

Disclosure. Compensated Affiliate. This report was authored by and is property of StoneBridge Partners LLC. All information and data relied upon in drafting this report is publicly available. The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report. Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice. Any projections or other information generated by StoneBridge Partners LLC regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results. None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment. This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation. The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals. It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction. Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks. The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission. Please contact a Financial Advisor for professional advice regarding any and all securities investments. This report is intended for informational purposes only. StoneBridge Partners LLC’s officers, directors, employees, affiliates, or subsidiaries may have positions in securities covered by StoneBridge Partners LLC. StoneBridge Partners LLC receives compensation from the company and/or has a position in the securities mentioned in this report

Authored By: Michael Berger

    12 27740

    The Future of Cannabis Biotech

    With some of the most successful fund managers in the world believing a Trump Presidency will benefit the biotech industry more than any other sector and legalization of both recreational and medical cannabis quickly spreading across the country, we feel it’s absolutely necessary to have cannabis biotech in your portfolio right now. Todd Hagopian, the most successful biotech fund manager in the market today, has even said he thinks the entire biotechnology market is about to double.

    That is why we feel there couldn’t be a better time to introduce our readers to Vitality Biopharma (VBIO). This emerging cannabis biotech company is rapidly gaining investor interest while focusing on the treatment of inflammatory bowel disease, narcotic bowel syndrome, and multiple sclerosis. Furthermore, the Company’s proprietary glycosylation technology for producing cannabinoid prodrugs could, in fact, revolutionize the entire cannabis biotech industry and change how CBD treatments are administered to patients. Steering the ship at the forefront of this technology are two biotech experts who already built two highly successful NASDAQ biotech companies.

    But before we get into VBIO’s veteran management team, let’s take a look at a type of technology that could mold the future of cannabis biotech.

    Potential Game-Changing Technology

    Vitality Biopharma recently announced they had developed a new class of cannabinoid prodrugs, known as cannabosides. Prodrugs are often designed to improve bioavailability when a drug itself is poorly absorbed from the gastrointestinal tract, or to overcome other issues like harsh side effects. Early independent trial results show that VBIO’s technology could change how all current CBD treatments are administered.

    VBIO’s cannabosides are more stable and soluble than regular cannabinoids, meaning there is less risk of non-psychotropic cannabidiol (CBD) being converted to psychotropic THC or otherwise being degraded or diluted in the acidic stomach environment. Upon ingestion, these cannabosides can enable the selective delivery of THC and CBD to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits without having THC enter the bloodstream. For example, a prodrug could target a specific tissue or organ, such as the brain or gut, giving the patient better results with far less side effects.

    In addition to providing targeted delivery, cannabosides could enable a better tasting formulation for improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, and a delayed release mechanism that enables patients using these medications to have long-lasting, overnight relief.

    As of 2015, there were approximately 15 prodrugs classified as blockbusters, meaning they had annual sales exceeding $1billion.

    Vitality Bio creates the cannaboside prodrugs through enzymatic glycosylation, a process perfected in 2015. Management believes that glycosylation of cannabinoids can improve product bioavailability, eliminate unwanted side effects, and be useful in any medical treatment where oral CBD is administered at a high dose. Independent studies have already demonstrated reliable and improved targeting to specific tissue/organs upon oral delivery of GBD glycoside prodrugs vs. active CBD.

    The Company’s goal is to ultimately provide a compelling oral cannabinoid pharmaceutical that physicians will be eager to prescribe and patients will prefer.

    VBIO Compared to the Competition

    Many synthetic cannabinoids on the market today are poorly soluble. GW Pharma’s (GWPH) two leading products, Epidiolex® and Sativex® are solutions. Sativex is a mixture of CBD/THC solubilized with 50% v/v alcohol (ethanol) into an oral spray. Although the alcohol volume is small, it can still cause problems for alcoholics, pregnant women, and young children. Oral lesions may also form in users of alcohol-based cannabis sprays, coupled with reported stinging, bad taste, and dry mouth. Sativex also contains propylene glycol, which may cause further irritation and dry mouth. The product must be stored in the refrigerator and has a shelf life of only 42 days. An oral capsule cannaboside prodrug developed by VBIO may alleviate many of these problems.

    Other companies, such as Zynerba Pharmaceuticals (ZYNE), are developing cannabinoid transdermal patches. Transdermal delivery routes can in some cases lead to hives/skin irritation, and typically deliver relatively small drug dosages. Oral cannaboside capsules avoid this problem and could enable far more convenient delivery of cannabinoids in a form that is fast-acting and that works at a high dose for maximal effect.

    We believe prodrug development like VBIO’s cannabosides is the future of the medical cannabis industry.

    Now, let’s make one thing clear. We are not saying that GW Pharma or Zynerba have poor drug treatments. What we are saying is that we believe VBIO’s technology could make them far better.

    Creating prodrugs is already a commercially validated strategy used by big pharma companies to improve drug efficacy and reduce side effects in non-cannabis related drugs. And because the reference drug or original drug already has independent verification and/or approval of its safety and efficacy, the prodrug can be approved much quicker by simply demonstrating similar safety and efficacy as the original. At the same time, a prodrug can be far more marketable due to its ability to eliminate unwanted side effects or undesirable commercial aspects. A classic prodrug example is Aspirin (acetylsalicylic acid), a synthetic prodrug of salicylic acid.

    It comes down to this…

    Cannabis biotech is still a very young industry, infant you could even say. And just like how the pharmaceutical industry matured and advanced using prodrug formulations of existing drugs to achieve higher efficacy and less side effects, the cannabis biotech industry will follow the same path. Drugs like GWPH’s Sativex and Epidiolex may be some of the first drugs to hit the market but that doesn’t mean they are the best, or even the best version of themselves. It is often times the prodrug variation of an approved drug that surpasses the $1billion annual sales mark; like we saw with Aspirin, the prodrug of salicylic acid.

    VBIO Drug Pipeline

    Through its glycosylation technology, Vitality Bio has produced more than 25 novel cannabosides and has patent applications pending that include composition of matter claims for prodrugs of cannabinoids that have been studied extensively in clinical trials worldwide, including THC, CBD, and cannabidivarin (CBDV).

    VBIO’s IP portfolio includes 79 patent claims and almost 200 individual compounds,

    including novel glycoside prodrugs of the most abundant phytocannabinoids, THC and CBD, as well as a variety of other phytocannabinoids and endocannabinoids.

    The company aims to develop and receive approval for these proprietary molecules as pharmaceuticals by taking advantage of the more efficient FDA review and approval process that is available for prodrugs. This greatly reduces the need for large and expensive clinical trials. Because clinical studies have already been performed or are currently still in process for many large commercial indications such as epilepsy, neuropathic pain, multiple sclerosis, inflammatory bowel disease, schizophrenia, and Huntington’s disease, management aims to create improved prodrug formulations of these cannabinoids that ultimately deliver a superior product.

    Vitality Biopharma’s two main drugs are moving towards beginning Phase I/Phase II studies in 2017.

    • VB100 – Inflammatory Bowel Disease, Narcotic Bowel Syndrome
    • VB210 – Neuropathic Pain, Irritable Bowel Syndrome, Opiate-induced Bowel Dysfunction, Muscle Spasticity in Multiple Sclerosis

    “Independent clinical trials have shown VBIO’s prodrugs retain almost all of the benefits of cannabinoids and, furthermore, they can be approved by the FDA at a far lower cost and on an accelerated timeline.” – according to Insider Financial Magazine

    With the current state of the biotech and cannabis markets, we feel it is important for investors to familiarize themselves with VBIO right now. The value and growth opportunities with biotech investments are before they start announcing potentially positive data from Phase I/Phase II/Phase III clinical trials. That is because positive study data and trial results tend to significantly increase biotech company stock prices. It is not uncommon for a biotech company’s stock to go up 100% or even 300% in a single trading day after announcing such data.

    Strong Management from Successful NASDAQ Biotech Companies

    CEO – Robert Brooke

    Mr. Brooke is a biomedical engineer and experienced biotech entrepreneur. He was the founder of a drug development company that became Lion Biotechnologies (NASDAQ: LBIO) in 2013. He also co-founded Intervene Immune. Mr. Brooke also had a successful hedge fund stint as an analyst for Bristol Capital, responsible for more than 50 direct healthcare investments.

    Chairman & Co-Founder – Avtar Dhillon, MD

    Mr. Dhillon has extensive biotech experience. He is currently Chairman of three biotech companies: Inovio Pharmaceuticals (NASDAQ: INO), Oncosec Medical (NASDAQ: ONCS) and Arch Therapeutics (ARTH). He has also raised over $200 million in public markets to ensure that his companies have sufficient research funding that is critical to a biotech company’s success. Mr. Dhillon is also a former venture capitalist and family physician for more than 10 years.

    Director of Research and Development, Scientific Co-Founder – Brandon Zipp, PhD

    Dr. Zipp is a scientist with over 10 years of research experience with glucosyltransferase enzymes – the enzymes used in VBIO’s proprietary development process. He has a Ph.D Biochemistry and Molecular Biology from the University of California, Davis.

    We always say you invest in management. And what we mean by that is no matter how great a company’s product or technology is, you need a capable management team to properly bring it to market. A cure for cancer in a lab does a company and its shareholders no good if the management team cannot commercialize the drug and bring it to market. Companies will encounter several financial hurdles and operational speed bumps along the way. A good management team can overcome these obstacles while staying focused on their goal and progressing through their business plan, in turn, building shareholder value. This is why it is important to invest in companies with proven and successful management teams.

    Conclusion

    The medical marijuana and cannabis industry is booming. And the biotech industry is poised for a massive bull run with Donald Trump winning the election. Right now could be the perfect time to add cannabis biotech to your portfolio.

    What was hype and speculation only a few years ago is now an investable market with tremendous upside. At the center of the industry is biopharma R&D being pioneered by companies with proprietary technology and the intellectual property leading to exciting medical breakthroughs. Just as prodrug development advanced the non-cannabis pharmaceutical market, we expect similar technology to help mature an infant biotech cannabis industry.

    Vitality Bio is currently conducting preclinical studies in anticipation of filing IND applications in 2017 for glycosylated cannabinoid products called cannabosides. The most advanced candidate is VB100, a cannaboside prodrug under development for the acute management of inflammatory bowel disease. A second candidate, VB210, is under development for chronic conditions that affect both the GI and CNS. With a strong IP portfolio of 79 patent claims on over 200 compounds and a proven, successful management team, VBIO could be set up to benefit from an overall cannabis biotech rally and is already quickly gaining investor interest.

     

     

     

     

     

     

     

     

     

     


    Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO), which we purchased in the open market. We plan to sell the “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

      0 1644

      MarijuanaStocks.com asked FBEC Worldwide Inc’s (FBEC) chief scientist Linda Strauss an adjunct professor at UC San Diego and Co-Founder of G Randel & Sons a development company that specializes in CBD based R&D for product creation her thoughts on INSY from a drug standpoint. “Looking at the market’s reaction to Insy Therapeutics’ (INSY) announcement two weeks ago that the U.S. Food and Drug Administration (FDA) has approved its dronabinol oral solution, SyndrosTM, you would think this was a breakthrough treatment. However, it is not, but that doesn’t make it any less important an announcement. SyndrosTM is an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, which is a pharmaceutical version of tetrahydrocannabinol (“THC”), one of the main active ingredients in cannabis. Dronabinol has been on the market since 1985, marketed by AbbVie ($ABBV) as Marinol. Marinol was developed and approved for the treatment of nausea and vomiting associated with cancer chemotherapy inpatients that had failed to respond adequately to conventional antiemetic treatments. SyndrosTM is only the second pharmaceutical cannabinoid to win approval by the FDA for marketing in the United States. Unlike Marinol, which is manufactured as a capsule containing THC in sesame oil, SyndrosTM is an orally administered liquid formulation that has a quicker onset and can be self­titrated, meaning the patient can use as much or as little as they need by making small adjustments in the amount they take.

      SyndrosTM carries the same risk of side effects as Marinol including psychiatric and cognitive effects and impaired mental and/or physical abilities. There are only a limited number of patients who would stand to benefit from a product like SyndrosTM. Patients currently taking Marinol are the most likely to benefit by switching to SyndrosTM as they would be able to self­titrate their own dosage and improved bioavailability. Ultimately this is a good sign that the FDA is willing to approve new cannabinoid drugs that meet their high standards for approval including those derived from the cannabis plant itself rather than it being derived synthetically.”

      All of this bodes well for the big board pharma companies looking to synthesize specific parts of the cannabis plants for drug treatments as a ruling from the Drug Enforcement Administration is expected to happen within the next 6 month. The referenced ruling is in regards to the possible rescheduling of Cannabis. Marijuana is currently listed as a schedule 1 drug alongside LSD, Crystal Meth, Heroin, MDMA (ecstasy) and Mescaline (peyote), despite the fact that cannabis has never caused a person to die from overdose. Advocates have long felt that the demonization of marijuana and lack of study has been more about politics than common sense measures. If cannabis is rescheduled to class 2, 3 or removed entirely the entire industry will expand rapidly. The first companies to benefit will be, ironically, in the sector that has lobbied against cannabis so ardently; Big Pharma. These Biotech companies want a schedule 2 classification which would expand the study, while everyone would settle for 3 or complete removal.

      Michael Berger from Technical420.com stated “The rescheduling of cannabis will serve as a major catalyst for the biotech industry and those companies that have cannabis related drugs in their drug trial pipeline will bring in new investors that were once gun shy about Marijuana Stocks due to the current classification.” He went on to tell MarijuanaStocks.com that “current speculation from industry insiders is that companies like INSY, CARA, ZYNE GWPH could all be acquisition targets from some of the Big Pharma super powers.”

      There’s no doubt in our mind that this would be an event driven catalyst that the Marijuana sector thrives on, enhancing the overall public & private markets. We can only hope that common sense and logic will win out there by opening the door to full legalization.

      0 2515

      Monday (3/14), one of the cannabis industry leaders, GW Pharma (GWPH) announced positive results from its first Phase 3 study of Epidiolex in the treatment of Dravet syndrome. Epidiolex already has orphan drug designation and Fast Track Designation from the FDA for this rare form of epilepsy. Currently there are no treatments approved in the U.S. The Active substance in Epidiolex, cannabidiol or CBD, has been the source of conversation and controversy for years.

      Many doctors have even condemned it as a false therapy for things like cancer and, yes, epilepsy. But with the advent of strains like Charlotte’s Web, which have shown to drastically curb the affects of epilepsy, these Phase 3 results may confirm much of what many in the health community has already confirmed, which is that CBD’s can be a strong reactive therapy for debilitating diseases like this.

      These findings could mean big things for the marijuana industry, as the ripple effect seems to have already begun. GW Pharma stock sprinted 120% to 84.71 in the stock market Monday, hitting a three-month high above 91, intra-day. The news also jump started other cannabis-related stocks like Insys Therapeutics (INSY), which rose 11% to 18.89, and the recently IPO’d Zynerba Pharmaceuticals (ZYNE), which increased to a six month high of $21.08; up 150%.

      Like GW Pharma, Insys is also testing a CBD product in Dravet syndrome, and similarly has been granted an orphan-drug designation from the FDA. Zynerba is developing a form of CBD that can be applied through the skin. In a recent PR, ZYNE reported that in the first half of 2016, the Company expects to report final results from its ongoing Phase 1 single rising dose clinical trial, including results from 12 patients with epilepsy.

      Other CBD Related Stocks Seeing More Attention From GW’s Findings:

      FBEC Worldwide, Inc. (FBEC)

      Originally focused on providing hemp based energy drinks, FBEC has also spread its reach into the quality CBD marketplace through its distribution of Ma Brand CBD. Late last year the company signed a Joint Venture agreement with CBD Globe Distributors Ltd. in which FBEC will own 50.1% of the newly formed Joint Venture LLC and receive 50% of the net profit from its operations. According to CBD Globe, it has invested over $200,000 in production and development of the Ma brand itself and already has 10,000 units packaged and ready for sale. The CBD vaping product has a highly refined CBD oil made from hemp, grown in the United States.

      Top UFC contender, Anthony “Rumble” Johnson, has endorsed the company’s hemp energy shot product. Furthermore, its most recent announcements have dealt heavily with revamping its share structure and curbing potential sources of future dilution. FBEC shares rose just over 25% from Monday’s open and closed at the high of day.

      GreenGro Technologies, Inc. (GRNH)

      GRNH also acquired Greensticks, Inc.; a patent pending technology for an electronic vaporizer for Cannbidiol (CBD). Branded as a new way to medicate, Greensticks is a battery powered electronic vaporizer designed to look like an electronic cigarette. The cartridges are filled with 100% organic liquefied flowers and pharmaceutical grade glycol as found in asthma inhalers.

      GRNH recently announced record-breaking 242.94% year-over-year sales growth through the first quarter of 2016. According to the company, this timely growth came as a result of new customers along with renewals and the ongoing expansion of the company’s product lines. Additionally, sales increased by 209.57% from the fourth quarter of 2015 to the first quarter of 2016. Along with many other marijuana stocks, GRNH shares increased by nearly 60% from open to high and closed the Monday session at its HOD of $0.349 on more than 5 times it’s average 30-day volume.

      Medical Marijuana Inc. (MJNA)

      This marijuana stock saw very heavy volume on Monday with price increasing by a modest 7% from its previous close, Friday. The company announced at the beginning of March that its portfolio investment company, KannaLife Sciences, Inc. has received the necessary 2016 quota allotment from the U.S. DEA to import high-purity, pharmaceutical-grade cannabidiol into the U.S.

      KannaLife is currently focused on the feasibility studies with Catalent Pharma to develop a cannabinoid-derived therapeutic agent for the treatment of two neurodegenerative diseases: Hepatic Encephalopathy and Chronic Traumatic Encephalopathy; forms of brain degradation in humans that can be due to things like head trauma.

      Cannabis Science, Inc. (CBIS)

      This stock saw an incredible day on Monday as well. The stock increased from an opening price of $0.01 to a high of $0.0194. The stock ended the day, closing up just under 50%. The company is continuing testing and providing limited rollouts for its own CBD-based treatment products in California. The company has taken a strong stance to increase shareholder value.

      In recent press Cannabis Science’s CEO announced that he will be gifting his own shares to shareholders in lieu of previously announced dividends. That date of record for shareholders has been extended to March 31, 2016.

      CV Sciences. (CANV)

      The stock saw nearly 3 times its average 30-day volume on Monday fueled by excitement in the marijuana sector. Share prices rallied up more than 75%. In most of the recent press releases, the company has been focused on extinguishing the remainder of its convertible debt and as of early March, CANV management confirmed that 100% of the outstanding convertible promissory notes have been retired.

      Following the acquisition of CanX and Canabine earlier this year, the company has taken a firm stance on efforts to develop synthetically-formulated CBD for use in drug development activities. In particular, they are looking to pursue approval of the FDA for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient. Board Chairman James A. McNulty has been an active contributor to biotechnology and health care related companies, including BioDelivery Sciences International, Inc. (BDSI), Hedgepath Pharmaceuticals, Inc. (HPPI), Accentia Biopharmaceuticals, Inc., and Biovest International, Inc. He is also a former shareholder of CanX, which brings this full circle.

      Conclusion

      There are obviously many more marijuana stocks that could be mentioned here but it would seem that the CBD-centric companies like those mentioned, have begun to benefit from the latest ground breaking announcement that GW Pharma has just made with regard to a successful Phase 3 study. With such a late stage success, we think that the hemp, CBD and cannabis space will be a topic of major discussion in 2016.

       

       

      Additional disclosure/disclaimer

      An affiliate of MAPH Enterprises, LLC MarijuanaStocks.com | WolfofWeedStreet.com was paid an advertising fee of $60,000 cash & 60 Million Restricted Common shares by FBEC Worldwide Inc. (FBEC) for visual sponsorship of MarijuanaStocks.com | WolfofWeedStreet.com and for visual placement FBEC Worldwide Inc. (FBEC) within written materials. FOR A DURATION OF 5 YEARS BEGINNING JUNE 2015 ending JUNE 2020

      0 910

      Currently, 40 states have passed laws that allow for the use of some form of medical marijuana. Even though marijuana clearly has medical benefits, it remains a Schedule I substance alongside heroin, LSD, ecstasy, and bath salts under the Controlled Substances Act (CSA). According to the United States Drug Enforcement Agency, Schedule I substances have the following characteristics:

      • The substance has a high potential for abuse.
      • The substance has no currently accepted medical treatment use in the U.S.
      • There is a lack of accepted safety for use of the substance under medical supervision.

      In late June, the White House took a major step forward to support cannabis research by eliminating the Public Health Service review requirement. Now, the Office of National Drug Control Policy (ONDCP) will help facilitate medical marijuana research.

      Marijuana advocates have said that the federal government’s strict rules on marijuana research have prevented researchers from performing necessary studies in the United States. These strict polices have caused the United States to experience a “brain drain” with regard to scientists interested in learning about the medical benefits associated with marijuana.

      Dr. Alan Shackelford moved to Israel after seeing U.S. drug laws block clinical studies into promising applications that treat illnesses which conventional medicine cannot treat. Dr. Shackelford is a Harvard-trained physician who was Charlotte Figi’s doctor.

      Shackelford said, “I went to Israel because I was frustrated. Israel is the one place in the world that combines the scientific expertise, world-class universities and scientists. It’s so exciting.”

      In a study published by the National Bureau of Economic Research, researchers were able to determine that the states with medical marijuana dispensaries experience a decrease in opioid addictions and overdose deaths compared to states that do not.

      Five overlooked benefits of marijuana

      Five overlooked benefits of marijuana include its potential to treat the following debilitating and deadly diseases:

      1) Cancer

      Cannabinoids, the active components of marijuana, inhibit tumor growth in laboratory animals and also kill cancer cells. In April 2015, the National Institute on Drug Abuse (NIDA) reported that marijuana can kill certain cancer cells. The monthly publication was revised to say the following:

      “Recent animal studies have shown that marijuana can kill certain cancer cells and reduce the size of others. Evidence from one animal study suggests that extracts from whole-plant marijuana can shrink one of the most serious types of brain tumors. Research in mice showed that these extracts, when used with radiation, increased the cancer-killing effects of the radiation.”

      2) Fibromyalgia

      Zynerba Pharmaceuticals (ZYNE: NASDAQ) is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. Zynerba is developing two therapeutic candidates based on proprietary transdermal technologies.

      The company’s THC Pro-Drug Patch is a pro-drug of THC that enables transdermal delivery via a patch. Zynerba is studying ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

      3) Epilepsy

      In mid-April, the American Academy of Neurology (AAN) issued a statement saying GW Pharmaceutical’s (GWPH: NASDAQ) Epidiolex product, “may show promise” in the treatment of severe epilepsy in children.

      The AAN provided the results of a study of 213 people (median age of 11) who suffered from severe epilepsy and did not respond to other treatments. For the 137 people who completed the 12-week study, the number of seizures decreased by an average of 54%.

      Among the 23 people with Dravet syndrome who finished the study, the number of convulsive seizures had gone down by 53%. For the 11 people with Lennox-Gastaut syndrome who finished the study, there was a 55% reduction in the number of atonic seizures, which cause a sudden loss of muscle tone. A total of 12 people, or 6%, stopped taking the drug due to side effects.

      4) Glaucoma

      In December, Nemus Bioscience Inc. (NMUS) reported that Dr. Soumyajit Majumdar, an Associate Professor of Pharmaceutics at the University of Mississippi, presented data at the American Association of Pharmaceutical Scientists (AAPS) that showed that a pro-drug formulation of delta-9-tetrahydrocannabinol (THC) significantly lowered intra-ocular pressure (IOP) in an open-angle rabbit glaucoma model.

      The rabbits that received the THC pro-drug saw a greater percentage drop in IOP when compared to timolol, and an even greater percentage drop when compared to pilocarpine. The THC pro-drug resulted in an IOP lowering effect of 45%-50%.

      5)Multiple Sclerosis

      Marijuana can be used as a treatment for multiple sclerosis. GW Pharmaceutical’s (GWPH: INSY) Sativex product is sold as a treatment for multiple sclerosis and is derived from cannabis. Sativex is sold in 27 countries and it is currently in Stage 3 FDA testing (results expected late 2015/early 2016).

      But it still remains a Schedule I substance

      The benefits of marijuana can no longer be ignored. The recent findings, NIDA’s admission, company developments, and the opinion of Dr. Sanjay Gupta and of the United States Surgeon General should be enough to reschedule marijuana and promote research into it.

      – See more at: https://technical420.com/cannabis-article/why-schedule-i-label-make-no-sense#sthash.4oYObqKn.tdaE7ZMT.dpuf

       

      Authored by: Micheal Berger

      Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

      We are your #1 source for all things Marijuana Stocks, Subscribe Below!

      Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
      Ad Placements